Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer
Science Advances · 29.03.2024 · 10 (13)
DOI: 10.1126/sciadv.adk5386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 29.03.2024. Verfasst von Alice Cortesi und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy. Hauptthemen laut MEDLINE: Endogenous Retroviruses, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
While pancreatic ductal adenocarcinomas (PDACs) are addicted to KRAS-activating mutations, inhibitors of downstream KRAS effectors, such as the MEK1/2 kinase inhibitor trametinib, are devoid of therapeutic effects. However, the extensive rewiring of regulatory circuits driven by the attenuation of the KRAS pathway may induce vulnerabilities of therapeutic relevance. An in-depth molecular analysis of the transcriptional and epigenomic alterations occurring in PDAC cells in the initial hours after MEK1/2 inhibition by trametinib unveiled the induction of endogenous retroviruses (ERVs) escaping epigenetic silencing, leading to the production of double-stranded RNAs and the increased expression of interferon (IFN) genes. We tracked ERV activation to the early induction of the transcription factor ELF3, which extensively bound and activated nonsilenced retroelements and synergized with IRF1 (interferon regulatory factor 1) in the activation of IFNs and IFN-stimulated genes. Trametinib-induced viral mimicry in PDAC may be exploited in the rational design of combination therapies in immuno-oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy.
- Department of Genomic Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
- Institute for Research in Biomedicine (IRB), Università della Svizzera Italiana, Bellinzona, Switzerland.
- DiSFeB, Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti," Università degli Studi di Milano, Milano 20133, Italy.
ORCID-Profile: Alice Cortesi, Francesco Gandolfi, Fabiana Arco, Pierluigi Di Chiaro, Emanuele Valli, Sara Polletti, Roberta Noberini, Francesco Gualdrini, Sergio Attanasio, Francesca Citron, I-Lin Ho, Rutvi Shah, Er-Yen Yen, Mara Cetty Spinella, Simona Ronzoni, Simona Rodighiero, Nico Mitro, Tiziana Bonaldi, Serena Ghisletti, Silvia Monticelli, Andrea Viale, Giuseppe Riccardo Diaferia, Gioacchino Natoli
Förderung
- NCI NIH HHS
Zitieren
APA
Cortesi, A., Gandolfi, F., Arco, F., Di Chiaro, P., Valli, E., Polletti, S., Noberini, R., Gualdrini, F., Attanasio, S., Citron, F., Ho, I. L., Shah, R., Yen, E. Y., Spinella, M. C., Ronzoni, S., Rodighiero, S., Mitro, N., Bonaldi, T., Ghisletti, S., …, & Natoli, G. (2024). Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer. Science Advances, 10(13). https://doi.org/10.1126/sciadv.adk5386
Vancouver
Cortesi A, Gandolfi F, Arco F, Di Chiaro P, Valli E, Polletti S, et al. Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer. Science Advances. 2024;10(13). doi:10.1126/sciadv.adk5386
BibTeX
@article{Cortesi2024,
author = {Cortesi, Alice and Gandolfi, Francesco and Arco, Fabiana and Di Chiaro, Pierluigi and Valli, Emanuele and Polletti, Sara and Noberini, Roberta and Gualdrini, Francesco and Attanasio, Sergio and Citron, Francesca and Ho, I-Lin and Shah, Rutvi and Yen, Er-Yen and Spinella, Mara Cetty and Ronzoni, Simona and Rodighiero, Simona and Mitro, Nico and Bonaldi, Tiziana and Ghisletti, Serena and Monticelli, Silvia and Viale, Andrea and Diaferia, Giuseppe Riccardo and Natoli, Gioacchino},
title = {Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {13},
doi = {10.1126/sciadv.adk5386}
}
EUVIMED